Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Auxilius

Explore full profile

Provides automated financial management software that streamlines R&D budgeting, forecasting, and accruals for biopharma companies

New York City, United StatesFounded 2020Fintech
Valuation $50–100M Last recorded · 2024
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Auxilius and the history behind them.

About Auxilius

Auxilius is a specialized financial management platform tailored for biotech companies conducting clinical trials. The company focuses on providing precise and efficient financial oversight, ensuring that sponsors—typically biotech firms—can manage their trial budgets, vendor relationships, and financial risks effectively. Auxilius operates in the biotech and pharmaceutical market, which is characterized by high stakes and significant financial investments in research and development.

The core service offered by Auxilius is a comprehensive platform that integrates various financial management functions. This includes vendor management, trial governance, cost management, and financial planning and analysis (FP&A). The platform allows clients to digitize and streamline their financial processes, moving away from static spreadsheets to a more dynamic and scalable solution.

Auxilius makes money through a subscription-based business model, where biotech companies pay for access to the platform and its suite of tools. These tools include invoice review and validation, change tracking and management, dynamic forecasting, and accruals management. By leveraging these features, clients can predict costs accurately, manage changes in trial scope, and ensure alignment with both internal and external stakeholders.

The platform also offers scenario modeling and lightweight document management, providing a unified view of trial budgets and enabling better financial decision-making. This comprehensive approach helps biotech companies maintain financial precision without sacrificing the speed and efficiency needed to meet their research milestones.

In summary, Auxilius empowers biotech firms to achieve financial excellence in their clinical trials by offering a robust, integrated platform that enhances financial oversight and decision-making.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
New York City, United States
Employees
53
Open positions
None listed
Dealroom signal
84.5/100
Industry
Fintech
Sub-industry
Financial Management Solutions
Sector
Fintech, Accounting, Corporate Finance, Financial Strategy, Tech for Biotech and Pharma, CFO Tech
Business model
SaaS
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Mar 2024 $10M $40M SignalFire ↗
SERIES A✓Equity / VC Jun 2022 $10M $40M Bain Capital Ventures · Andy Palmer · Chase Gilbert · XYZ Venture Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Auxilius website traffic

Latest recorded traffic for Auxilius is 2.4K monthly website visits, down 14.3% over the last three months. Auxilius's team grew 12.8% over the past year.

Latest monthly visits2.4K 3-month web change-14.3% 1-year team growth+12.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A4 investors entered at this stage

  • Renegade Partners
  • Andy Palmer
  • Chase Gilbert
  • SignalFire
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States92.3%
🇲🇽 Mexico2.6%
🇹🇷 Turkey2.6%
🇮🇪 Ireland2.6%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Auxilius on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Auxilius’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.